Login / Signup

Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.

David Z I CherneyDick de ZeeuwHiddo J Lambers HeerspinkJose CardonaMarc DeschArne WenzFriedrich SchulzeMasaomi Nangaku
Published in: Diabetes, obesity & metabolism (2023)
BI 685509 was generally well tolerated. Effects on UACR lowering merit further investigation.
Keyphrases
  • type diabetes
  • open label
  • nuclear factor
  • wound healing
  • randomized controlled trial
  • clinical trial
  • placebo controlled
  • double blind